Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma.
Eighty-six cases of primary endometrial carcinoma were assayed for the presence or absence of cytoplasmic estrogen and progesterone receptors by the saturation point dextran-coated charcoal assay. The levels of cytoplasmic progesterone receptors and estrogen receptors were analyzed according to clinical stage, histologic type and grade of the tumor, presence or absence of lymph node metastases, myometrial invasion, and survival. The cases were divided into positive and negative receptor groups with levels chosen of greater than 10 fmol/mg of cytosol protein for progesterone receptor and 5 fmol/mg of cytosol protein for estrogen receptor as discrimination points. Statistically significant survival differences were found between estrogen receptor positive versus estrogen receptor negative patients, progesterone receptor positive versus progesterone receptor negative patients, and estrogen positive-progesterone receptor positive versus estrogen negative-progesterone receptor negative patients. Mean cytoplasmic estrogen and progesterone receptor levels were inversely proportional to grade. This report suggests that treatment protocols should be devised to reflect the prognostic significance of receptor status.
D000230:Adenocarcinoma / Q000032:analysis / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000032:analysis / Q000401:mortality / Q000473:pathology; D003593:Cytoplasm / Q000032:analysis; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008593:Menopause; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D014594:Uterine Neoplasms / Q000032:analysis* / Q000401:mortality / Q000473:pathology
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone